Viking Therapeutics reported a net loss of $128.0 million, or $1.10 per share, for the second quarter ended June 30, 2026, compared to a net loss of $65.6 million in the prior year period. Research and development expenses increased to $115.8 million from $60.2 million due to clinical studies and salaries. The company holds $502 million in cash and short-term investments as of June 30, 2026. Clinically, Phase 3 VANQUISH trials for subcutaneous VK2735 are fully enrolled, with oral VK2735 Phase 3 initiation expected in the fourth quarter of 2026. Maintenance dosing data is anticipated in the third quarter of 2026, and a Phase 1 study for amylin agonist VK3019 has commenced. Viking appointed Hubert Chen as chief medical officer and Dorothy Gemmell to its board of directors. Viking Therapeutics operates in the biotechnology industry, developing therapies for obesity and metabolic disorders.